%0 Journal Article %A James D. Chalmers %A Stefano Aliberti %A Francesco Blasi %T Management of bronchiectasis in adults %D 2015 %R 10.1183/09031936.00119114 %J European Respiratory Journal %P 1446-1462 %V 45 %N 5 %X Formerly regarded as a rare disease, bronchiectasis is now increasingly recognised and a renewed interest in the condition is stimulating drug development and clinical research. Bronchiectasis represents the final common pathway of a number of infectious, genetic, autoimmune, developmental and allergic disorders and is highly heterogeneous in its aetiology, impact and prognosis. The goals of therapy should be: to improve airway mucus clearance through physiotherapy with or without adjunctive therapies; to suppress, eradicate and prevent airway bacterial colonisation; to reduce airway inflammation; and to improve physical functioning and quality of life. Fortunately, an increasing body of evidence supports interventions in bronchiectasis. The field has benefited greatly from the introduction of evidence-based guidelines in some European countries and randomised controlled trials have now demonstrated the benefit of long-term macrolide therapy, with accumulating evidence for inhaled therapies, physiotherapy and pulmonary rehabilitation. This review provides a critical update on the management of bronchiectasis focussing on emerging evidence and recent randomised controlled trials. Bronchiectasis is a rapidly developing field: review of recent RCTs and progress towards developing new therapies http://ow.ly/JXGWM %U https://erj.ersjournals.com/content/erj/45/5/1446.full.pdf